{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of evaluating female sexual dysfunction (FSD) is the use of validated, patient-reported outcome measures. The Female Sexual Function Index (FSFI) is a widely used multi-domain questionnaire that allows for a standardized assessment of a patient's sexual function. Mastering the scoring of the FSFI is a fundamental skill, enabling you to translate a patient's subjective experiences into a quantitative score that can be used for diagnosis, tracking progress, and research . This practice provides a direct application of the FSFI's psychometric scoring algorithm, a crucial step in evidence-based assessment.",
            "id": "4436760",
            "problem": "A patient enrolled in a high-resolution clinical outcomes study of female sexual dysfunction completes the Female Sexual Function Index (FSFI). In the FSFI scoring framework, each domain is first converted from its raw sum to a standardized domain score via a domain-specific linear scaling constant so that domains are placed on a common metric, and then the composite index is formed by additive aggregation across domains. This approach follows standard psychometric practice for constructing composite scales: linear transformation of domain raw sums to maintain order-preserving properties and comparability across domains, followed by summation to reflect the composite latent trait.\n\nThe patient’s domain raw sums are: desire $=7$, arousal $=15$, lubrication $=16$, orgasm $=9$, satisfaction $=12$, and pain $=10$. Use the established FSFI domain scaling constants for the respective domains: desire $=0.6$, arousal $=0.3$, lubrication $=0.3$, orgasm $=0.4$, satisfaction $=0.4$, and pain $=0.4$. Compute the total FSFI by appropriately transforming the raw sums with these constants and aggregating across domains. Report a single real number for the total FSFI. Do not round; report the exact value. The FSFI is a unitless index.",
            "solution": "The user has provided a problem that requires the calculation of a composite score from sub-scale data based on a specified psychometric procedure.\n\n### Step 1: Extract Givens\nThe problem provides the following data:\n-   **Patient's domain raw sums:**\n    -   Desire: $7$\n    -   Arousal: $15$\n    -   Lubrication: $16$\n    -   Orgasm: $9$\n    -   Satisfaction: $12$\n    -   Pain: $10$\n-   **FSFI domain scaling constants:**\n    -   Desire: $0.6$\n    -   Arousal: $0.3$\n    -   Lubrication: $0.3$\n    -   Orgasm: $0.4$\n    -   Satisfaction: $0.4$\n    -   Pain: $0.4$\n-   **Procedure:** \"Compute the total FSFI by appropriately transforming the raw sums with these constants and aggregating across domains.\" This is further clarified as \"each domain is first converted from its raw sum to a standardized domain score via a domain-specific linear scaling constant... and then the composite index is formed by additive aggregation across domains.\"\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated based on the established criteria.\n\n-   **Scientifically Grounded:** The problem is based on the Female Sexual Function Index (FSFI), a widely used and validated psychometric instrument for assessing female sexual dysfunction. The scoring procedure described—linear scaling of domain raw scores followed by summation—is a standard and accepted methodology in psychometrics for constructing composite indices. The problem is firmly grounded in the principles of clinical assessment and psychometric theory.\n-   **Well-Posed:** The problem provides all necessary data (raw scores and scaling constants) and a clear, unambiguous algorithm for calculation. A unique, stable, and meaningful solution exists.\n-   **Objective:** The problem statement is expressed in precise, objective language. It requests a specific calculation based on provided data and rules, free of any subjective or opinion-based content.\n-   **Topic Relevance:** The problem is directly related to the field of obstetrics and gynecology, specifically within the topic of *female sexual dysfunction: assessment and management*.\n\nThe problem is free of the listed flaws:\n1.  **Scientific/Factual Unsoundness:** No violation of scientific principles.\n2.  **Non-Formalizable/Irrelevant:** The problem is formalizable and relevant.\n3.  **Incomplete/Contradictory:** The setup is complete and consistent.\n4.  **Unrealistic/Infeasible:** The data and procedure are realistic for this clinical context.\n5.  **Ill-Posed:** The problem is well-posed.\n6.  **Pseudo-Profound/Trivial:** The problem is a direct application of a specific formula, testing comprehension and computational accuracy, and is not trivial in its clinical context.\n7.  **Outside Scientific Verifiability:** The calculation is directly verifiable.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A solution will be computed as requested.\n\nThe total Female Sexual Function Index (FSFI) score is calculated by first determining the scaled score for each of the six domains and then summing these scaled scores. The scaled score for a domain is the product of its raw sum and its corresponding scaling constant.\n\nLet $S_{raw,i}$ be the raw sum for domain $i$, and let $k_i$ be the scaling constant for that domain. The scaled domain score, $S_{scaled,i}$, is given by:\n$$S_{scaled,i} = S_{raw,i} \\times k_i$$\n\nThe total FSFI score, $F_{total}$, is the sum of the scaled scores for all domains:\n$$F_{total} = \\sum_{i} S_{scaled,i}$$\n\nLet's denote the domains as Desire (D), Arousal (A), Lubrication (L), Orgasm (O), Satisfaction (Sat), and Pain (P). The raw sums provided are:\n$S_{raw,D} = 7$\n$S_{raw,A} = 15$\n$S_{raw,L} = 16$\n$S_{raw,O} = 9$\n$S_{raw,Sat} = 12$\n$S_{raw,P} = 10$\n\nThe corresponding scaling constants are:\n$k_{D} = 0.6$\n$k_{A} = 0.3$\n$k_{L} = 0.3$\n$k_{O} = 0.4$\n$k_{Sat} = 0.4$\n$k_{P} = 0.4$\n\nNow, we calculate the scaled score for each domain:\n-   **Desire:** $S_{scaled,D} = S_{raw,D} \\times k_D = 7 \\times 0.6 = 4.2$\n-   **Arousal:** $S_{scaled,A} = S_{raw,A} \\times k_A = 15 \\times 0.3 = 4.5$\n-   **Lubrication:** $S_{scaled,L} = S_{raw,L} \\times k_L = 16 \\times 0.3 = 4.8$\n-   **Orgasm:** $S_{scaled,O} = S_{raw,O} \\times k_O = 9 \\times 0.4 = 3.6$\n-   **Satisfaction:** $S_{scaled,Sat} = S_{raw,Sat} \\times k_{Sat} = 12 \\times 0.4 = 4.8$\n-   **Pain:** $S_{scaled,P} = S_{raw,P} \\times k_P = 10 \\times 0.4 = 4.0$\n\nFinally, we sum these scaled scores to obtain the total FSFI score:\n$$F_{total} = S_{scaled,D} + S_{scaled,A} + S_{scaled,L} + S_{scaled,O} + S_{scaled,Sat} + S_{scaled,P}$$\n$$F_{total} = 4.2 + 4.5 + 4.8 + 3.6 + 4.8 + 4.0$$\n$$F_{total} = 8.7 + 4.8 + 3.6 + 4.8 + 4.0$$\n$$F_{total} = 13.5 + 3.6 + 4.8 + 4.0$$\n$$F_{total} = 17.1 + 4.8 + 4.0$$\n$$F_{total} = 21.9 + 4.0$$\n$$F_{total} = 25.9$$\n\nThe total FSFI score is the exact value $25.9$.",
            "answer": "$$\n\\boxed{25.9}\n$$"
        },
        {
            "introduction": "After establishing a baseline assessment and initiating treatment, a critical question arises: has the intervention produced a meaningful improvement for the patient? While a change in a score like the FSFI may be statistically significant, it may not be clinically relevant. This is where the concept of the Minimal clinically Important Difference (MCID) becomes essential . This exercise challenges you to move beyond simple pre-post comparisons and apply the MCID to determine if an observed improvement in sexual function is substantial enough to be considered truly significant from the patient's perspective.",
            "id": "4436779",
            "problem": "A clinical investigator evaluates a treatment for a woman with female sexual interest/arousal disorder using the Female Sexual Function Index (FSFI), a validated multidomain instrument in which higher total scores indicate better sexual function. The total FSFI score ranges from approximately $2$ to $36$. The woman’s baseline total FSFI is $21.0$ and her post-intervention total FSFI at $12$ weeks is $27.0$. For this population and outcome, assume an established minimal clinically important difference (MCID) of $4.0$ on the total FSFI score. Using core clinical measurement principles, compute the change in total FSFI from baseline to follow-up, determine whether the change strictly exceeds the MCID, and interpret whether the improvement is clinically significant. Define the indicator function $I$ such that $I=1$ if the improvement is clinically significant according to the strict exceedance decision rule and $I=0$ otherwise. Provide, as your final numeric answer, the value of $I$. No rounding is required and no units are involved.",
            "solution": "The Female Sexual Function Index (FSFI) is a validated instrument; higher total scores reflect better sexual function. The minimal clinically important difference (MCID) is a threshold representing the smallest change that patients perceive as beneficial and that would justify a change in the patient’s management; here it is given as $4.0$ on the total FSFI for the relevant population.\n\nStarting from core definitions in clinical measurement:\n- The change score is defined as the difference between the post-intervention measure and the baseline measure. Denote baseline by $S_{0}$ and follow-up by $S_{1}$, with $S_{0}=21.0$ and $S_{1}=27.0$.\n- The change is $\\Delta = S_{1} - S_{0}$.\n- A clinically significant improvement under a strict exceedance rule is concluded if and only if $\\Delta > \\text{MCID}$, where $\\text{MCID}=4.0$.\n- Define the indicator $I$ by $I=1$ if $\\Delta > \\text{MCID}$ and $I=0$ otherwise.\n\nCompute the change:\n$$\n\\Delta = S_{1} - S_{0} = 27.0 - 21.0 = 6.0.\n$$\n\nCompare to the MCID:\n$$\n6.0 > 4.0,\n$$\nso the change strictly exceeds the MCID. Therefore, by the decision rule, the improvement is clinically significant.\n\nDefine the indicator $I$:\n$$\nI =\n\\begin{cases}\n1, & \\text{if } \\Delta > \\text{MCID},\\\\\n0, & \\text{otherwise}.\n\\end{cases}\n$$\nGiven $\\Delta=6.0$ and $\\text{MCID}=4.0$, we have $I=1$.\n\nThus, the final numeric answer for the indicator is $1$.",
            "answer": "$$\\boxed{1}$$"
        },
        {
            "introduction": "Real-world clinical practice often involves patients with multiple comorbidities and complex medication regimens. Many common medications can contribute to or cause FSD, creating a challenging diagnostic and management puzzle. This final practice moves from quantitative assessment to holistic clinical reasoning . You are asked to analyze a case of iatrogenic low sexual desire resulting from polypharmacy, integrating your knowledge of pharmacology, neuroendocrinology, and patient-centered care to identify the contributing factors and formulate the most appropriate management plan that prioritizes both efficacy and patient safety.",
            "id": "4436716",
            "problem": "A $32$-year-old nulliparous woman presents with $9$ months of markedly reduced sexual desire that is distressing to her and is straining her relationship. She denies pain with intercourse, has adequate lubrication, and does not report anorgasmia. She has a history of Major Depressive Disorder (MDD), in full remission for $18$ months on sertraline $100\\ \\mathrm{mg}$ daily, and polycystic ovary syndrome managed for acne and hirsutism with spironolactone $100\\ \\mathrm{mg}$ daily. For contraception and cycle control, she takes a combined oral contraceptive containing ethinyl estradiol $30\\ \\mu\\mathrm{g}$/drospirenone $3\\ \\mathrm{mg}$ daily. She strongly prefers to preserve psychiatric stability and is fearful of depressive relapse. She has no seizure history, normal renal function, and no cardiovascular disease. She drinks alcohol socially ($\\leq 2$ drinks/week) and does not use recreational drugs.\n\nOn examination, body mass index is $26\\ \\mathrm{kg/m^2}$, blood pressure is $112/68\\ \\mathrm{mmHg}$. Pelvic examination is unremarkable. Laboratory tests: thyroid-stimulating hormone $1.8\\ \\mathrm{mIU/L}$, prolactin $28\\ \\mathrm{ng/mL}$, total testosterone $22\\ \\mathrm{ng/dL}$ (low-normal), sex hormone-binding globulin (SHBG) $180\\ \\mathrm{nmol/L}$ (elevated), calculated free testosterone low, estradiol $120\\ \\mathrm{pg/mL}$. Patient Health Questionnaire-$9$ score is $3$.\n\nUsing core neuroendocrine principles of sexual desire regulation and established pharmacologic effects of serotonergic and antiandrogenic drugs, identify the additive iatrogenic risks for low desire in this patient and select the single best management strategy that directly addresses those risks while minimizing the likelihood of psychiatric destabilization. Which option is most appropriate as the next step?\n\nA. Discontinue sertraline and start paroxetine monotherapy; increase spironolactone to $150\\ \\mathrm{mg}$ daily for acne control; continue the combined oral contraceptive unchanged\n\nB. Maintain sertraline; add bupropion sustained-release $150\\ \\mathrm{mg}$ each morning; switch from the combined oral contraceptive to a copper intrauterine device (IUD); reassess libido and mood in $4$–$6$ weeks\n\nC. Stop spironolactone and start finasteride $5\\ \\mathrm{mg}$ daily; continue sertraline and the combined oral contraceptive unchanged\n\nD. Cross-taper sertraline to vortioxetine over $1$–$2$ weeks; continue spironolactone and the combined oral contraceptive unchanged\n\nE. Add sildenafil $50\\ \\mathrm{mg}$ as needed prior to intercourse; make no other changes to the current regimen",
            "solution": "## Problem Validation ##\n\n### Step 1: Extract Givens ###\n- **Patient**: $32$-year-old nulliparous woman.\n- **Presenting Symptom**: Markedly reduced sexual desire for $9$ months, causing distress.\n- **Sexual History**: Denies dyspareunia, reports adequate lubrication, no anorgasmia.\n- **Medical History**:\n    - Major Depressive Disorder (MDD), in full remission for $18$ months.\n    - Polycystic Ovary Syndrome (PCOS), managed for acne and hirsutism.\n- **Current Medications**:\n    - Sertraline $100\\ \\mathrm{mg}$ daily (for MDD).\n    - Spironolactone $100\\ \\mathrm{mg}$ daily (for PCOS symptoms).\n    - Combined oral contraceptive (COC): ethinyl estradiol $30\\ \\mu\\mathrm{g}$ / drospirenone $3\\ \\mathrm{mg}$ daily (for contraception and cycle control).\n- **Patient Preferences**: \"strongly prefers to preserve psychiatric stability and is fearful of depressive relapse.\"\n- **Additional History**: No seizure history, normal renal function, no cardiovascular disease. Social alcohol use ($\\le 2$ drinks/week), no recreational drugs.\n- **Physical Examination**:\n    - Body Mass Index (BMI): $26\\ \\mathrm{kg/m^2}$.\n    - Blood Pressure: $112/68\\ \\mathrm{mmHg}$.\n    - Pelvic Examination: Unremarkable.\n- **Laboratory Findings**:\n    - Thyroid-Stimulating Hormone (TSH): $1.8\\ \\mathrm{mIU/L}$.\n    - Prolactin: $28\\ \\mathrm{ng/mL}$.\n    - Total Testosterone: $22\\ \\mathrm{ng/dL}$ (low-normal).\n    - Sex Hormone-Binding Globulin (SHBG): $180\\ \\mathrm{nmol/L}$ (elevated).\n    - Calculated Free Testosterone: Low.\n    - Estradiol: $120\\ \\mathrm{pg/mL}$.\n    - Patient Health Questionnaire-9 (PHQ-9) score: $3$.\n\n### Step 2: Validate Using Extracted Givens ###\nThe problem statement describes a complex but realistic clinical scenario involving iatrogenic hypoactive sexual desire disorder (HSDD).\n\n- **Scientifically Grounded**: The problem is based on well-established principles of pharmacology and neuroendocrinology. The described effects of the medications on sexual function are extensively documented in scientific literature:\n    1.  SSRIs (sertraline) are known to cause decreased libido via serotonergic inhibition of dopamine pathways.\n    2.  Spironolactone is an androgen receptor antagonist and weak inhibitor of androgen synthesis, known to reduce libido.\n    3.  Combined oral contraceptives (specifically the ethinyl estradiol component) increase hepatic synthesis of SHBG, which binds and reduces free testosterone. The progestin, drospirenone, is an analog of spironolactone and possesses anti-androgenic activity.\n    The laboratory values (elevated SHBG, low free testosterone, normal TSH, PHQ-9 score of $3$ indicating remission) are consistent with the clinical picture and the effects of her medications. The slightly elevated prolactin is also a known potential side effect of SSRIs and can contribute to low libido. The problem is free of pseudoscience and factual errors.\n\n- **Well-Posed**: The question asks for the single best management strategy among a set of options, a standard format for clinical reasoning problems. It provides sufficient data and constraints (especially the patient's psychiatric stability preference) to allow for a logical, deductive choice. The goal is clearly defined: address the iatrogenic risks for low desire while minimizing psychiatric risk.\n\n- **Objective**: The problem is stated in objective, clinical language. The patient's preference is presented as a crucial clinical constraint.\n\nThe problem does not exhibit any flaws such as scientific unsoundness, incompleteness, contradiction, or ambiguity. It is a well-constructed, advanced clinical vignette.\n\n### Step 3: Verdict and Action ###\nThe problem is valid. A solution will be derived.\n\n## Solution Derivation ##\n\n### Principle-Based Derivation ###\n\nThe patient's presentation of low sexual desire is consistent with Hypoactive Sexual Desire Disorder (HSDD). Given the onset and her medication regimen, the etiology is overwhelmingly likely to be iatrogenic, with multiple contributing factors. The core task is to identify these factors based on neuroendocrine and pharmacological principles and then select the intervention that best mitigates them while respecting the patient's priority of maintaining psychiatric stability.\n\n1.  **Analysis of Iatrogenic Factors**:\n    - **Serotonergic Pathway**: Sertraline is a Selective Serotonin Reuptake Inhibitor (SSRI). Elevated synaptic serotonin, particularly via stimulation of $5$-$\\mathrm{HT}_{2A}$ and $5$-$\\mathrm{HT}_{2C}$ receptors, is known to inhibit mesolimbic dopamine release. Dopamine is a primary neurotransmitter mediating sexual desire and motivation. Therefore, sertraline is a major contributor to her low libido.\n    - **Androgenic Pathway**: Libido in women is modulated by androgens, specifically free testosterone. This patient's androgenic signaling is suppressed by three distinct mechanisms:\n        1.  **Spironolactone**: At a dose of $100\\ \\mathrm{mg}$ daily, it acts as a potent competitive antagonist at the androgen receptor, directly blocking testosterone's effects. It also has minor effects on androgen synthesis.\n        2.  **Combined Oral Contraceptive (COC)**:\n            - The ethinyl estradiol component ($30\\ \\mu\\mathrm{g}$) is a powerful stimulus for hepatic production of SHBG. Her laboratory result of SHBG at $180\\ \\mathrm{nmol/L}$ is markedly elevated (typical range for premenopausal women not on COCs is roughly $20$–$120\\ \\mathrm{nmol/L}$). SHBG binds testosterone with high affinity, drastically reducing the bioavailable free testosterone fraction, which is confirmed to be low.\n            - The progestin component, drospirenone ($3\\ \\mathrm{mg}$), is a spironolactone derivative and possesses intrinsic anti-androgenic activity, further contributing to the androgen blockade.\n    - **Prolactin Pathway**: Her prolactin is mildly elevated at $28\\ \\mathrm{ng/mL}$ (upper limit of normal is typically $\\sim 25\\ \\mathrm{ng/mL}$). Hyperprolactinemia can suppress libido both by inhibiting dopamine (prolactin and dopamine have a reciprocal inhibitory relationship in the tuberoinfundibular pathway) and by suppressing the GnRH pulse generator. SSRIs are a common cause of mild hyperprolactinemia. While a minor factor compared to the others, it is a potential contributor.\n\nIn summary, the patient has a \"triple-hit\" on her sexual desire: central serotonergic inhibition and a profound dual-mechanism (receptor blockade and reduced bioavailability) suppression of androgens.\n\n2.  **Evaluation of Management Strategies**: The optimal strategy must address these root causes, particularly the most significant ones, while minimizing the risk of depressive relapse, which is the patient's primary concern.\n\n### Option-by-Option Analysis ###\n\n**A. Discontinue sertraline and start paroxetine monotherapy; increase spironolactone to $150\\ \\mathrm{mg}$ daily for acne control; continue the combined oral contraceptive unchanged**\n- **Analysis**: This option is counter-therapeutic.\n    - **Psychiatric**: Switching from sertraline (on which her MDD is in full remission) to paroxetine introduces a risk of psychiatric destabilization. Furthermore, paroxetine is the SSRI associated with the *highest* incidence of sexual dysfunction. This change would likely worsen, not improve, the serotonergic component of her low libido.\n    - **Androgenic**: Increasing the spironolactone dose from $100\\ \\mathrm{mg}$ to $150\\ \\mathrm{mg}$ will intensify the androgen receptor blockade. Continuing the COC maintains the elevated SHBG and anti-androgenic drospirenone.\n- **Verdict**: **Incorrect**. This strategy would almost certainly worsen her low desire and directly contradicts the patient's stated goal of preserving psychiatric stability.\n\n**B. Maintain sertraline; add bupropion sustained-release $150\\ \\mathrm{mg}$ each morning; switch from the combined oral contraceptive to a copper intrauterine device (IUD); reassess libido and mood in $4$–$6$ weeks**\n- **Analysis**: This is a multi-pronged, logical, and patient-centered strategy.\n    - **Psychiatric**: Maintaining sertraline is the safest course of action for her mood, respecting her primary concern. Adding bupropion, a norepinephrine-dopamine reuptake inhibitor (NDRI), is a first-line strategy for treating SSRI-induced sexual dysfunction. Its pro-dopaminergic effects can directly counteract the libido-suppressing effects of serotonin. As bupropion is also an antidepressant, it poses a very low risk of mood destabilization and can even have an augmenting effect. Her lack of a seizure history makes her a suitable candidate.\n    - **Androgenic**: Switching from the COC to a non-hormonal copper IUD is a critical and highly effective maneuver. This eliminates the two hormonal culprits: the ethinyl estradiol that drives up SHBG and the anti-androgenic drospirenone. Over several weeks, her SHBG level will fall, leading to a significant increase in free, biologically active testosterone. This single change addresses the majority of the androgen suppression.\n- **Verdict**: **Correct**. This option directly addresses both the serotonergic and hormonal etiologies of her HSDD while maximally prioritizing her psychiatric stability.\n\n**C. Stop spironolactone and start finasteride $5\\ \\mathrm{mg}$ daily; continue sertraline and the combined oral contraceptive unchanged**\n- **Analysis**: This strategy is insufficient and possibly ineffective.\n    - **Androgenic**: Finasteride inhibits $5\\alpha$-reductase, blocking testosterone conversion to dihydrotestosterone (DHT). While this is a different mechanism from spironolactone's receptor blockade, finasteride itself is associated with sexual side effects, including decreased libido (post-finasteride syndrome). It is not a guaranteed improvement.\n    - **Other factors**: This change fails to address the major contributors: the sertraline-induced serotonergic effect and the COC-induced androgen suppression (high SHBG and drospirenone).\n- **Verdict**: **Incorrect**. This is a minor and questionable change that leaves the most significant iatrogenic factors untouched.\n\n**D. Cross-taper sertraline to vortioxetine over $1$–$2$ weeks; continue spironolactone and the combined oral contraceptive unchanged**\n- **Analysis**: This strategy addresses one factor but at an unnecessary risk.\n    - **Psychiatric**: Vortioxetine, a multimodal antidepressant, is known to have a lower incidence of sexual dysfunction than traditional SSRIs. This change addresses the serotonergic component. However, any switch in antidepressant carries a risk of relapse or mood instability during the transition, which is what the patient explicitly fears.\n    - **Androgenic**: This plan leaves the potent anti-androgenic effects of both spironolactone and the COC completely unaddressed.\n- **Verdict**: **Incorrect**. Compared to option B, this approach is less comprehensive (addressing one factor instead of two) and carries a higher psychiatric risk, which goes against the patient's stated preference.\n\n**E. Add sildenafil $50\\ \\mathrm{mg}$ as needed prior to intercourse; make no other changes to the current regimen**\n- **Analysis**: This option misidentifies the therapeutic target.\n    - **Pharmacologic Target**: Sildenafil is a phosphodiesterase type 5 (PDE-5) inhibitor. It enhances vasodilation and blood flow, primarily targeting the physiological genital *arousal* response (e.g., clitoral erection). The patient's primary problem is low *desire* (libido), a central motivational state. She explicitly denies problems with lubrication or orgasm, which are more closely related to arousal. While desire and arousal are linked, sildenafil does not directly act on the central neurotransmitter systems (dopamine, serotonin, androgens) that govern libido. Its use in female HSDD is off-label and not well-supported by evidence.\n    - **Etiology**: This approach does nothing to correct the underlying iatrogenic causes of her low desire.\n- **Verdict**: **Incorrect**. This is a symptomatic treatment for the wrong symptom phase and fails to address the identified root causes.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}